Skip to content
Menu

Vicore Pharma Holding AB (publ) VCRE

Full chart Compare
Set alert

Price alert · VCRE

All alert types
10.53 USD +0.17 (+1.64%)

As ofNov 16, 2026, 12:55 PM EST

10.49 Day range 10.78
7.88 52-week range 17.80
YTD
-35.20%
1 year
-35.20%
Market cap
299.11M
EPS (ttm)
-2.04
Shares out
28.15M
YTD return
-35.20%
1-year return
-35.20%
50-day average
12.28
200-day average
12.28
Revenue growth
-32.50%
Volume
9.81K
Avg volume
22.87K
Open
10.78
Previous close
10.36
Day's range
10.49 – 10.78
52-week range
7.88 – 17.80
Beta
0.12
Price target
35.42 (+236.4%)

5D +1.00 (+9.71%)

1011ThuFriMonTueWed11.30

Key statistics

Free cash flow
-241.98M
Return on equity
-47.19%

Fundamental scorecard

4 of 25 checks passed on VCRE’s reported financials

ValueGrowthProfitabilityHealthDividend

4of 25 checks passed

  • Value 0 of 5
  • Growth 0 of 5
  • Profitability 0 of 5
  • Financial health 4 of 5
  • Dividend 0 of 5

Statements to Mar 31, 2026.

Financials — quick view

All financials
VCRE Revenue — quarterly 602.00K
VCRE Net income — quarterly -108.62M
VCRE EPS — quarterly -0.39

Earnings

VCRE recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Aug 21, 2026Sep 30, 2026-0.04211———
May 6, 2026Jun 30, 2026-0.0505-0.04103+0.01+18.75%
Feb 27, 2026Mar 31, 2026-0.04923-0.05843-0.01-18.69%
Nov 5, 2025Sep 30, 2025-0.05189-0.053480.00-3.06%
May 6, 2025Jun 30, 2025-0.04365———
Feb 27, 2025Mar 31, 2025-0.03211-0.0459-0.01-42.95%

About Vicore Pharma Holding AB (publ)

Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary hypertension. It also developing Almee, an investigational medical device in clinical development that has completed Phase III clinical stage to address the psychological impact of living with pulmonary fibrosis. It has a cooperation and development agreement with Emeriti Bio AB and HaLaCore Pharma AB to develop new follow-on molecules based on C21 and other drug substances targeting the AT2 receptor, as well as a collaboration and development agreement with Alex Therapeutics AB to develop a digital app in interstitial lung diseases, such as IPF. The company was formerly known as Mintage Scientific AB. Vicore Pharma Holding AB (publ) was founded in 2000 and is headquartered in Stockholm, Sweden.

Sector
Healthcare
Industry
Biotechnology
Country
Sweden

News

Your note

Sign in to keep a note on VCRE — it syncs with the Stock Master app.